Oct 23, 2013 by Seth Robey3 Takeaways From Amgen's Earnings ReportInvestors have a lot to chew on after Amgen's third quarter earnings. This should help them digest the results.
Oct 20, 2013 by Seth Robey3 Things to Watch in Amgen's Earnings ReportThe Onyx integration, Enbrel sales, and PCSK9 development are all important things to watch at Amgen.
Oct 17, 2013 by Seth RobeyIs Amarin's FDA Panel Important for Other Cardiovascular Drugmakers?Other companies with drugs that lower triglycerides were watching Amarin's FDA panel closely.
Oct 16, 2013 by Seth RobeyA Health Care Portfolio for the AgesBiotech companies Gilead Sciences and Celgene kick off the start of a market-beating diversified health care portfolio.
Oct 11, 2013 by Seth RobeyAre Pfizer's Xeljanz Results a Boost for Amgen?Pfizer's Xeljan's performed fine in a trial for psoriasis, but will safety issues derail the drug's label expansion?
Oct 9, 2013 by Seth RobeyThese Companies Have Nobel-Winning Science on Their SideFrom Eli Lilly's diabetes candidate to Allergan's Botox, this years Nobel Prize-winning science is everywhere.
Oct 5, 2013 by Seth RobeyWill This Company Face the Same Restructuring as Merck?Eli Lilly is facing some of the same problems as fellow big pharma companies Merck and AstraZeneca.
Sep 30, 2013 by Seth RobeyWhich Alzheimer's Fighter Will Benefit From a Boost in Federal Funding?One of these companies will receive $33 million for a special Alzheimer's trial.
Sep 27, 2013 by Seth RobeyThe "Foolish" Way to Invest in BiotechHow can we Foolishly invest in an industry dominated by short-term catalysts?
Sep 12, 2013 by Seth RobeyA Pharmacology Primer for Biotech InvestorsHere's one way new investors can think about drug development.
Sep 10, 2013 by Seth RobeyThe Sweeter Side of the Cola WarsAre Coke and Pepsi facing hard times as consumers fear sugar?
Sep 10, 2013 by Seth RobeyInvest in the Next Biotech FrontierWhat market could yield the next blockbuster race?
Sep 9, 2013 by Seth RobeyDigging Deeper Into This Heart Failure Drug's MissDid omecamtiv mecarbil miss its clinical goal as badly as the market thinks it did?
